Theravance Biopharma, Inc. · NASDAQ:TBPH
Theravance Biopharma — Corporate Update (November 2018)
9 slides from Theravance Biopharma's corporate update, Nov 9, 2018
Slide 1: Cautionary Statement Regarding Forward-Looking Statements
Cautionary Statement Regarding Forward-Looking Statements Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward-looking statements or projections made by the company are subject to risks and uncertainties that m
Slide 2: YUPELRI: Now FDA-Approved
YUPELRITM: Now FDA-Approved Approved for the maintenance treatment of patients with COPD The first and only once-daily nebulized LAMA for patients with COPD COPD = chronic obstructive pulmonary disease
Slide 3: NDA Supported by Positive Phase 3 Results
Primary endpoint achieved for both doses in replicate efficacy studies Robust and sustained improvements in FEV1 Study included use as monotherapy as well as add-on to LABA or LABA/ICS Generally well tolerated in 12-month safety study NDA Supported by Positive Phase 3 Results Two replicate efficacy
Slide 4: YUPELRI: Broad Indication with Key Data in Label
YUPELRITM: Broad Indication with Key Data in Label Approved for the maintenance treatment of patients with COPD Once daily at dose of 175 mcg, for use with any standard jet nebulizer Final label incorporates: Data illustrated for change from baseline in trough FEV1 after 12 weeks of dosing Data illu
Slide 5: Partnership with Mylan Provides Commercial Strength in Nebulized Opportunity
Partnership with Mylan Provides Commercial Strength in Nebulized Opportunity 1 IMS Health information service: NSP for period MAT May, 2015. Excludes nebulized SABAs. IMS expressly reserves all rights, including rights of copying, distribution and republication. 2 TBPH market research (N = 160 physi
Slide 6: YUPELRI: Now FDA-Approved
YUPELRITM: Now FDA-Approved Approved for the maintenance treatment of patients with COPD The first and only once-daily nebulized LAMA for patients with COPD
Slide 7: Opportunities to Create Transformational Medicines
Opportunities to Create Transformational Medicines YUPELRITM (revefenacin) Nebulized LAMA in COPD Now approved, with commercial launch activities underway TD-1473 Intestinally-restricted JAKi for inflammatory intestinal diseases Initiating Phase 2 study in Crohn’s disease and Phase 2b/3 study in ulc
Slide 8: About YUPELRI (revefenacin) inhalation solution
About YUPELRITM (revefenacin) inhalation solution YUPELRITM (revefenacin) inhalation solution is a novel once-daily nebulized LAMA approved for the maintenance treatment of COPD in the US. Market research by Theravance Biopharma indicates approximately 9% of the treated COPD patients in the US use n
Slide 9: About YUPELRI (revefenacin) inhalation solution
About YUPELRI™ (revefenacin) inhalation solution YUPELRI™ (revefenacin) inhalation solution is a novel once-daily nebulized LAMA approved for the maintenance treatment of COPD in the US. Market research by Theravance Biopharma indicates approximately 9% of the treated COPD patients in the US use neb
Theravance Biopharma — Corporate Update (November 2018) on 6ix